05-101 | Anti-EGFR Antibody, neutralizing, clone LA1

250 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers


      Contact Customer Service

      Click To Print This Page


      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HICC, IP, NEUT, WBMPurifiedMonoclonal Antibody
      Catalogue Number05-101
      Replaces04-337; 04-338
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-EGFR Antibody, neutralizing, clone LA1
      OverviewReacts with external domain of EGF receptor on all human cells. Competes with EGF and TGF-a for binding on human cells.
      Background InformationThe epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. EGFR (epidermal growth factor receptor) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor α (TGFα). Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer. In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. There is also evidence to suggest that clusters of activated EGFRs form, although it remains unclear whether this clustering is important for activation itself or occurs subsequent to activation of individual dimers.
      EGFR dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity. As a result, autophosphorylation of five tyrosine (Y) residues in the C-terminal domain of EGFR occurs. These are Y992, Y1045, Y1068, Y1148 and Y1173. This autophosphorylation elicits downstream activation and signaling by several other proteins that associate with the phosphorylated tyrosines through their own phosphotyrosine-binding SH2 domains. These downstream signaling proteins initiate several signal transduction cascades, principally the MAPK, Akt and JNK pathways, leading to DNA synthesis and cell proliferation. Such proteins modulate phenotypes such as cell migration, adhesion, and proliferation. The kinase domain of EGFR can also cross-phosphorylate tyrosine residues of other receptors it is aggregated with, and can itself be activated in that manner.
      Product Information
      • Positive Control Included: Non-Stim A431 Cell Lysate (12-301)
      PresentationLyophilized protein G Purified mouse immunoglobulin. Lyophilized from 0.1M Tris-glycine, pH 7.4, 0.15M NaCl containing no preservatives.
      ApplicationDetect EGFR using this Anti-EGFR Antibody, neutralizing, clone LA1 validated for use in IC, IP, NEUT & WB.
      Key Applications
      • Immunocytochemistry
      • Immunoprecipitation
      • Neutralizing
      • Western Blotting
      Biological Information
      ImmunogenHuman A431 membrane proteins.
      SpecificityRecognizes both phosphorylated and non-phosphorylated human EGF receptors.
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Gene Symbol
      • EGFR
      • ERBB1
      • ERBB
      • mENA
      Purification MethodProtein G Purified
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P00533 # Isoform 2/truncated isoform may act as an antagonist.
      SIZE: 1210 amino acids; 134277 Da
      SUBUNIT: Binds RIPK1. CBL interacts with the autophosphorylated C- terminal tail of the EGF receptor. Part of a complex with ERBB2 and either PIK3C2A or PIK3C2B. The autophosphorylated form interacts with PIK3C2B, maybe indirectly. Interacts with PELP1.
      SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane protein. & Isoform 2: Secreted.
      TISSUE SPECIFICITY: Expressed in placenta. Isoform 2 is also expressed in ovarian cancers.
      PTM: Phosphorylation of Ser-695 is partial and occurs only if Thr- 693 is phosphorylated. & Monoubiquitinated and polyubiquitinated upon EGF stimulation; which does not affect tyrosine kinase activity or signaling capacity but may play a role in lysosomal targeting. Polyubiquitin linkage is mainly through 'Lys-63', but linkage through 'Lys-48', 'Lys-11' and 'Lys-29' also occur.DISEASE:SwissProt: P00533 # Defects in EGFR are associated with lung cancer [MIM:211980].
      SIMILARITY: SwissProt: P00533 ## Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily. & Contains 1 protein kinase domain.
      MISCELLANEOUS: Binding of EGF to the receptor leads to dimerization, internalization of the EGF-receptor complex, induction of the tyrosine kinase activity, stimulation of cell DNA synthesis, and cell proliferation.
      Molecular Weight180 kDa
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assuranceroutinely evaluated on RIPA lysates from non-stimulated human A431 cells
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsLyophilized: 2 years at -20°C; Rehydrated: 1 month at 4°C or 6 months at -20°C
      Packaging Information
      Material Size250 µg
      Transport Information
      Supplemental Information




      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-EGFR, neutralizing, clone LA1 2464554
      Anti-EGFR, neutralizing, clone LA1 (mouse monoclonal IgG1) - DAM1413897 DAM1413897
      Anti-EGFR, neutralizing, clone LA1 - 2024628 2024628
      Anti-EGFR, neutralizing, clone LA1 - 2154196 2154196
      Anti-EGFR, neutralizing, clone LA1 - 2382130 2382130
      Anti-EGFR, neutralizing, clone LA1 - 2446776 2446776
      Anti-EGFR, neutralizing, clone LA1 - 15606 15606
      Anti-EGFR, neutralizing, clone LA1 - 16617 16617
      Anti-EGFR, neutralizing, clone LA1 - 17832 17832
      Anti-EGFR, neutralizing, clone LA1 - 19226 19226


      Reference overviewApplicationPub Med ID
      Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2.
      Zhou, Y; Yamada, N; Tanaka, T; Hori, T; Yokoyama, S; Hayakawa, Y; Yano, S; Fukuoka, J; Koizumi, K; Saiki, I; Sakurai, H
      Nature communications  6  7679  2015

      Show Abstract
      26158630 26158630
      Epithelial innate immune response to Acinetobacter baumannii challenge.
      Feng, Z; Jia, X; Adams, MD; Ghosh, SK; Bonomo, RA; Weinberg, A
      Infection and immunity  82  4458-65  2014

      Show Abstract
      25114113 25114113
      Studies of cell signaling in a reconstructed human epidermis exposed to sensitizers: IL-8 synthesis and release depend on EGFR activation.
      Frankart, Aurélie, et al.
      Archives of dermatological research, (2012)  2012

      Show Abstract
      22271211 22271211
      EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer.
      Singh, S; Trevino, J; Bora-Singhal, N; Coppola, D; Haura, E; Altiok, S; Chellappan, SP
      Molecular cancer  11  73  2012

      Show Abstract
      23009336 23009336
      EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.
      Lupberger, Joachim, et al.
      Nature medicine, (2011)  2011

      Show Abstract
      21516087 21516087
      Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells.
      L Sauer,D Gitenay,C Vo,V T Baron
      Oncogene  29  2010

      Show Abstract Full Text Article
      20190820 20190820
      Dexamethasone and methylprednisolone do not inhibit neuritic outgrowth while inhibiting outgrowth of fibroblasts from spiral ganglion explants.
      Alexis Furze,Deanna Kralick,Anand Vakharia,Korey Jaben,Reid Graves,Eelam Adil,Adrien A Eshraghi,Thomas J Balkany,Thomas R Van de Water
      Acta oto-laryngologica  128  2008

      Show Abstract
      17851911 17851911
      Acrolein-activated matrix metalloproteinase 9 contributes to persistent mucin production.
      Deshmukh, HS; Shaver, C; Case, LM; Dietsch, M; Wesselkamper, SC; Hardie, WD; Korfhagen, TR; Corradi, M; Nadel, JA; Borchers, MT; Leikauf, GD
      American journal of respiratory cell and molecular biology  38  446-54  2008

      Show Abstract
      18006877 18006877
      Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.
      Priti S Hegde,David Rusnak,Melissa Bertiaux,Krystal Alligood,Jay Strum,Robert Gagnon,Tona M Gilmer
      Molecular cancer therapeutics  6  2007

      Show Abstract
      17513611 17513611
      Roles of an IkappaB kinase-related pathway in human cytomegalovirus-infected vascular smooth muscle cells: a molecular link in pathogen-induced proatherosclerotic conditions.
      Gravel, SP; Servant, MJ
      The Journal of biological chemistry  280  7477-86  2005

      Show Abstract
      15619605 15619605


      How do I prepare a non-reducing sample buffer?Non-reducing sample buffer can be made and stored for months at room temperature. Here is the formulation for a 2X Non-reducing sample buffer: Water (37ml), 0.5M Tris-HCl (10ml), Glycerol (8ml), 10% SDS (16ml), 0.05% Bromophenol Blue (5ml).

      Related Products & Applications

      Related Products

      Alternative Format

      Catalogue Number Description  
      16-246 Anti-EGFR Antibody, neutralizing, clone LA1, Alexa Fluor® 488 Show Pricing & Availability

      Included Positive Control

      Catalogue Number Description  
      12-301 Non-Stimulated A431 Cell Lysate Show Pricing & Availability

      Product Families


      Life Science Research > Antibodies and Assays > Primary Antibodies